Lis William
Director at ZLAB; Director at JSPR; Chief Executive Officer at PORTOLA PHARMACEUTICALS INC
- Sold, on record
- $28.6M
- Dollars the filings state
- Form 4 sales
- 26
- Latest Aug 12, 2026
- Form 144 notices
- 8
- Proposed sales
- Quarters with a sale
- 4 of the last 8
- 4 days with a sale in that time
- Companies
- 3
- Filed as an executive or holder
Companies
- ZLABZai Lab LtdDirector
- JSPRJasper Therapeutics, Inc.Director
- PORTOLA PHARMACEUTICALS INCChief Executive Officer
Sales by reason
4
Routine
4
Plan not stated
1
No plan
17
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- PORTOLA PHARMACEUTICALS INC616,837 shares
- JSPR65,951 shares
- ZLAB62,117 shares
Shares sold, every Form 4 sale on record.
Timeline
- Aug 12, 2026Routine
Sold 16.9% of their holdings
$213k8,506 shares at $25.00
- Aug 12, 2026Notice
Filed a notice to sell 8,506 shares
$213k8,506 shares
- Jun 22, 2026Routine
Sold 12.2% of their holdings
$127k7,040 shares at $18.09
- Jun 22, 2026Notice
Filed a notice to sell 7,040 shares
$127k7,040 shares
- Jun 20, 2025Unusual
Sold 28.2% of their holdings
$493k13,814 shares at $35.67
- Jun 20, 2025Notice
Filed a notice to sell 13,814 shares
$493k13,814 shares
- Feb 28, 2025Unusual
Sold 28.3% of their holdings
$495k15,000 shares at $32.98
- Feb 28, 2025Notice
Filed a notice to sell 15,000 shares
$495k15,000 shares
- Jul 1, 2024Routine
Sold 16.4% of their holdings
$180k10,397 shares at $17.32
- Jul 1, 2024Notice
Filed a notice to sell 10,397 shares
$179k10,397 shares
10 of 34
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Aug 13, 2026 | ZLAB | Director | Sold | 8,506 | $25.00 | $213k | 41,931 | SEC |
| Jun 22, 2026 | Jun 24, 2026 | ZLAB | Director | Sold | 7,040 | $18.09 | $127k | 50,437 | SEC |
| Jun 17, 2026 | Jun 22, 2026 | ZLAB | Director | Awarded | 22,371 | 57,477 | SEC | ||
| Jun 20, 2025 | Jun 23, 2025 | ZLAB | Director | Sold | 13,814 | $35.67 | $493k | 35,106 | SEC |
| Jun 18, 2025 | Jun 23, 2025 | ZLAB | Director | Awarded | 10,831 | 48,920 | SEC | ||
| Feb 28, 2025 | Mar 4, 2025 | ZLAB | Director | Sold | 15,000 | $32.98 | $495k | 38,089 | SEC |
| Jul 1, 2024 | Jul 3, 2024 | ZLAB | Director | Sold | 10,397 | $17.32 | $180k | 53,089 | SEC |
| Jun 18, 2024 | Jun 20, 2024 | ZLAB | Director | Awarded | 21,253 | 63,486 | SEC | ||
| Oct 13, 2023 | Oct 13, 2023 | JSPR | Director | Sold | 7,965 | $0.85 | $7k | 53,521 | SEC |
| Jun 29, 2023 | Jun 30, 2023 | ZLAB | Director | Awarded | 18,903 | $26.45 | $500k | 42,233 | SEC |
| Jun 7, 2023 | Jun 8, 2023 | JSPR | Director | AwardedStock Option (right to buy) | 47,000 | 47,000 | SEC | ||
| Apr 13, 2023 | Apr 14, 2023 | JSPR | Director | Sold | 8,500 | $1.44 | $12k | 61,486 | SEC |
| Mar 3, 2023 | Mar 7, 2023 | ZLAB | Director | Sold | 5,434 | $38.31 | $208k | 23,330 | SEC |
| Oct 12, 2022 | Oct 13, 2022 | JSPR | Director | Awarded | 29,500 | 69,986 | SEC | ||
| Jun 27, 2022 | Jun 28, 2022 | JSPR | Director | Sold | 49,486 | $2.05 | $101k | 40,486 | SEC |
| Mar 21, 2022 | Mar 23, 2022 | JSPR | Officer, Director | AwardedStock Option (right to buy) | 197,472 | 100,000 | SEC | ||
| Mar 21, 2022 | Mar 23, 2022 | JSPR | Officer, Director | Awarded | 89,972 | 89,972 | SEC | ||
| Jan 20, 2022 | Jan 21, 2022 | ZLAB | Director | Sold | 1,926 | $53.40 | $103k | 34,114 | SEC |
| Jan 3, 2022 | Jan 4, 2022 | ZLAB | Director | Awarded | 7,763 | 36,040 | SEC | ||
| Jan 26, 2021 | Jan 28, 2021 | Eidos Therapeutics, Inc. | Director | Returned to the companyStock Option (Right to Buy) | 86,112 | 0 | SEC | ||
| Jan 15, 2021 | Jan 20, 2021 | ZLAB | Director | Awarded | 3,852 | 28,277 | SEC | ||
| Jan 5, 2021 | Feb 14, 2022 | ZLAB | Director | Withheld for tax | 5,350 | $129.14 | $691k | 22,927 | SEC |
| May 27, 2020 | May 29, 2020 | Eidos Therapeutics, Inc. | Director | AwardedStock Option (right to buy) | 21,528 | 21,528 | SEC | ||
| Jun 12, 2019 | Jun 13, 2019 | Eidos Therapeutics, Inc. | Director | AwardedStock Option (right to buy) | 21,528 | 21,528 | SEC | ||
| Dec 4, 2018 | Dec 7, 2018 | Eidos Therapeutics, Inc. | Director | AwardedStock Option (right to buy) | 43,056 | 43,056 | SEC | ||
| Aug 23, 2018 | Aug 28, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Withheld for tax | 17,587 | $26.05 | $458k | 204,448 | SEC |
| Jul 28, 2018 | Aug 28, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Exercised options | 35,000 | 222,035 | SEC | ||
| Jun 6, 2018 | Jun 8, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Sold | 5,113 | $45.21 | $231k | 222,035 | SEC |
| May 22, 2018 | May 24, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Withheld for tax | 6,491 | $40.82 | $265k | 227,148 | SEC |
| May 22, 2018 | May 24, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Awarded | 12,890 | 233,639 | SEC | ||
| Mar 2, 2018 | Mar 6, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Withheld for tax | 19,184 | $32.53 | $624k | 70,624 | SEC |
| Jan 31, 2018 | Feb 2, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | AwardedStock Option (Right to Buy) | 100,000 | 100,000 | SEC | ||
| Jan 31, 2018 | Feb 2, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Awarded | 25,000 | 25,000 | SEC | ||
| Aug 16, 2017 | Aug 18, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Withheld for tax | 7,435 | $54.86 | $408k | 0 | SEC |
| Jun 28, 2017 | Jun 29, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Sold | 269,299 | $55.43 | $14.9M | 0 | SEC |
| Jun 28, 2017 | Jun 29, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Exercised or settledStock Option (Right to Buy) | 269,299 | 101,820 | SEC | ||
| Jun 28, 2017 | Jun 29, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Exercised options | 269,299 | $8.33 | $2.2M | 14,150 | SEC |
| Apr 11, 2017 | Apr 11, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Sold | 6,750 | $36.06 | $243k | 4,730 | SEC |
| Mar 2, 2017 | Mar 3, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Withheld for tax | 13,669 | $38.61 | $528k | 112,839 | SEC |
| Jan 30, 2017 | Feb 1, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | AwardedStock Option (Right to Buy) | 171,875 | 34,375 | SEC | ||
| Jan 30, 2017 | Feb 1, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Awarded | 34,375 | 34,375 | SEC | ||
| May 2, 2016 | May 3, 2016 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Sold | 5,675 | $23.86 | $135k | 18,333 | SEC |
| May 1, 2016 | May 3, 2016 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | AwardedStock Option | 80,000 | 80,000 | SEC | ||
| May 1, 2016 | May 3, 2016 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Awarded | 40,000 | 40,000 | SEC | ||
| Mar 2, 2016 | Mar 4, 2016 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Withheld for tax | 3,492 | $31.75 | $111k | 24,008 | SEC |
| Jan 27, 2016 | Jan 29, 2016 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | AwardedStock Option (Right to Buy) | 140,625 | 28,125 | SEC | ||
| Jan 27, 2016 | Jan 29, 2016 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Awarded | 28,125 | 28,125 | SEC | ||
| Jul 15, 2015 | Jul 15, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Sold | 50,000 | $50.00 | $2.5M | 0 | SEC |
| Jul 15, 2015 | Jul 15, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Exercised or settledStock Option (Right to Buy) | 50,000 | 57,070 | SEC | ||
| Jul 15, 2015 | Jul 15, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Exercised options | 50,000 | $8.50 | $425k | 50,000 | SEC |
Page 1
Sales and notices (34)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Aug 13, 2026 | ZLAB | Director | Form 4 sale | 8,506 | $213k | 16.9% | Routine | SEC |
| Aug 12, 2026 | Aug 12, 2026 | ZLAB | Director | Form 144 notice | 8,506 | $213k | Notice | SEC | |
| Jun 22, 2026 | Jun 24, 2026 | ZLAB | Director | Form 4 sale | 7,040 | $127k | 12.2% | Routine | SEC |
| Jun 22, 2026 | Jun 22, 2026 | ZLAB | Director | Form 144 notice | 7,040 | $127k | Notice | SEC | |
| Jun 20, 2025 | Jun 23, 2025 | ZLAB | Director | Form 4 sale | 13,814 | $493k | 28.2% | Unusual | SEC |
| Jun 20, 2025 | Jun 20, 2025 | ZLAB | Director | Form 144 notice | 13,814 | $493k | Notice | SEC | |
| Feb 28, 2025 | Mar 4, 2025 | ZLAB | Director | Form 4 sale | 15,000 | $495k | 28.3% | Unusual | SEC |
| Feb 28, 2025 | Feb 28, 2025 | ZLAB | Director | Form 144 notice | 15,000 | $495k | Notice | SEC | |
| Jul 1, 2024 | Jul 3, 2024 | ZLAB | Director | Form 4 sale | 10,397 | $180k | 16.4% | Routine | SEC |
| Jul 1, 2024 | Jul 1, 2024 | ZLAB | Director | Form 144 notice | 10,397 | $179k | Notice | SEC | |
| Mar 6, 2024 | Mar 6, 2024 | JSPR | Director | Form 144 notice | 16,000 | $336k | Notice | SEC | |
| Oct 13, 2023 | Oct 13, 2023 | JSPR | Director | Form 144 notice | 7,965 | $7k | Notice | SEC | |
| Oct 13, 2023 | Oct 13, 2023 | JSPR | Director | Form 4 sale | 7,965 | $7k | 13.0% | Routine | SEC |
| Apr 13, 2023 | Apr 14, 2023 | JSPR | Director | Form 4 sale | 8,500 | $12k | 12.1% | No plan | SEC |
| Apr 13, 2023 | Apr 13, 2023 | JSPR | Director | Form 144 notice | 8,500 | $12k | Notice | SEC | |
| Mar 3, 2023 | Mar 7, 2023 | ZLAB | Director | Form 4 sale | 5,434 | $208k | 18.9% | Plan not stated | SEC |
| Jun 27, 2022 | Jun 28, 2022 | JSPR | Director | Form 4 sale | 49,486 | $101k | 55.0% | Unusual | SEC |
| Jan 20, 2022 | Jan 21, 2022 | ZLAB | Director | Form 4 sale | 1,926 | $103k | 5.3% | Plan not stated | SEC |
| Jun 6, 2018 | Jun 8, 2018 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 5,113 | $231k | 2.3% | Plan not stated | SEC |
| Jun 28, 2017 | Jun 29, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 269,299 | $14.9M | 100.0% | Unusual | SEC |
| Apr 11, 2017 | Apr 11, 2017 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 6,750 | $243k | 58.8% | Unusual | SEC |
| May 2, 2016 | May 3, 2016 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 5,675 | $135k | 23.6% | Plan not stated | SEC |
| Jul 15, 2015 | Jul 15, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 50,000 | $2.5M | 100.0% | Unusual | SEC |
| Jul 2, 2015 | Jul 2, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 15,000 | $684k | 100.0% | Unusual | SEC |
| Jul 1, 2015 | Jul 1, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 30,000 | $1.4M | 100.0% | Unusual | SEC |
| Apr 30, 2015 | May 1, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 45,000 | $1.6M | 100.0% | Unusual | SEC |
| Jan 20, 2015 | Jan 20, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 20,000 | $546k | 100.0% | Unusual | SEC |
| Jan 16, 2015 | Jan 16, 2015 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 20,000 | $539k | 100.0% | Unusual | SEC |
| Nov 20, 2014 | Nov 20, 2014 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 40,000 | $1.1M | 100.0% | Unusual | SEC |
| Nov 17, 2014 | Nov 17, 2014 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 30,000 | $801k | 100.0% | Unusual | SEC |
| Jul 3, 2014 | Jul 3, 2014 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 30,000 | $912k | 100.0% | Unusual | SEC |
| Jun 30, 2014 | Jul 1, 2014 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 10,000 | $292k | 100.0% | Unusual | SEC |
| May 27, 2014 | May 27, 2014 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 30,000 | $625k | 100.0% | Unusual | SEC |
| May 21, 2014 | May 21, 2014 | PORTOLA PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 10,000 | $199k | 100.0% | Unusual | SEC |